CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults When, where, and how to target vascular inflammation in the post-CANTOS era? Optimal Stenting Technique for Complex Coronary Lesions Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT Rare Genetic Variants Associated With Sudden Cardiac Death in Adults A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI 2019 ACC/AHA/ASE Advanced Training Statement on Echocardiography (Revision of the 2003 ACC/AHA Clinical Competence Statement on Echocardiography): A Report of the ACC Competency Management Committee Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure

Review ArticleVolume 71, Issue 14, April 2018

JOURNAL:J Am Coll Cardio. Article Link

Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults

KS Ivey, KM Edwards, HK Talbot et al. Keywords: cardiac exacerbation; hospitalizations; respiratory syncytial virus

ABSTRACT


Respiratory syncytial virus (RSV) is historically known for causing respiratory illness in young children, but the appreciation of its impact on older adults is growing. Studies have shown that hospitalization for respiratory illness due to RSV is complicated by cardiovascular events in 14% to 22% of adult patients, including worsening congestive heart failure, acute coronary syndrome, and arrhythmias. Additionally, underlying cardiovascular disease is associated with hospitalization in 45% to 63% of adults with confirmed RSV. In summary, patients with cardiopulmonary disease have higher rates of health care utilization for RSV-related illness and worse outcomes. Patients with cardiovascular disease likely represent an important target population for the rapidly developing field of RSV vaccines.